Investment Strategies: Purchase Shares of Novo Nordisk, Sell Shares of Bristol Myers Squibb
Sanlam Private Wealth, a leading financial services company, has a senior portfolio manager named Nick Kunze. Recently, Kunze made a buy recommendation for Novo Nordisk, a premier name in global healthcare known for its celebrity-favourite drug Ozempic.
However, the share price of Novo Nordisk has experienced a recent fall. As of July 2025, the stock price dropped by 56% from a year ago and fell 30% since the start of 2025. This decline can be attributed to increased competition and other factors, contributing to a 22% drop in trading on July 2025.
Despite these near-term challenges, long-term projections anticipate significant growth in Novo Nordisk's stock price and earnings through to 2029 and beyond. Forecasts indicate a strong upward trajectory from around $246 in the early part of 2025 to approximately $428 by 2030, representing a 74% increase over five years.
Revenues are expected to grow from 330-billion Danish kroner in 2025 to 520-billion kroner by 2029. Earnings before interest and tax margins for Novo Nordisk are projected at about 50% by 2029, with dividend yields set to increase steadily. Free cash flow is projected to reach 174-billion kroner by 2029.
The forward earnings multiple for Novo Nordisk is forecast to decline from 17 in 2025 to under 10 by 2029, signifying more cautious expectations on the company's earnings expansion amid competitive challenges. However, the company's valuation metrics and projected growth remain robust over the medium to long term, suggesting that despite short-term headwinds, Novo Nordisk is positioned for continued expansion driven by its core products like Ozempic and ongoing innovation.
In summary, the recent dip in Novo Nordisk's stock price is partly due to lower sales growth guidance and increased competition. However, long-term projections anticipate significant growth in Novo Nordisk's stock price and earnings through to 2029 and beyond. The company remains a promising investment for those seeking quality growth and a defensive stance in a volatile environment.
[1] CNBC (2025). Novo Nordisk stock price forecast: Where is Novo Nordisk stock going? Retrieved from https://www.cnbc.com/2025/07/01/novo-nordisk-stock-price-forecast.html
[2] Reuters (2025). Novo Nordisk lowers 2025 sales growth forecast, shares drop 22%. Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-lowers-2025-sales-growth-forecast-shares-drop-22-2025-07-01/
[1] Despite the current slump in Novo Nordisk's stock price, Sanlam Private Wealth's senior portfolio manager Nick Kunze still sees potential for future growth, given the company's long-term projections and robust core products like Ozempic. [2] This belief in the company's potential suggests that Kunze might be confident about the returns on investments in Novo Nordisk, particularly focusing on its health-and-wellness sector. [3] Furthermore, as a leading name in global healthcare, Novo Nordisk's future investments in science and research could potentially yield significant returns, making it an attractive choice for those interested in long-term business growth and opportunities in the finance sector.
